Breast Cancer Surgery Overview
Typical recovery: Recovery varies with the extent of surgery. After uncomplicated breast-conserving surgery, many patients resume light daily activity within a few days and recover progressively over one to two weeks. Recovery after mastectomy is usually longer, particularly when axillary dissection or reconstruction is performed. Drains, shoulder stiffness, seroma, wound-healing problems or reconstruction can prolong recovery. Radiotherapy and systemic treatment have their own timelines and may continue for weeks or months after surgical healing.
Key points
- Breast cancer surgery should be planned together with radiology, pathology, medical oncology and radiation oncology rather than in isolation.
- A core biopsy diagnosis should usually be obtained before definitive cancer surgery.
- Tumour biology matters: hormone-receptor, HER2 and other pathological features can change the sequence of treatment.
- For many patients with early breast cancer, breast-conserving surgery followed by appropriate radiotherapy provides survival equivalent to mastectomy.
- Mastectomy is not automatically a safer or more curative operation than breast conservation when both are oncologically appropriate.
- Breast-conserving surgery is most suitable when the cancer can be removed with clear margins while leaving an acceptable breast shape and radiotherapy can be delivered when indicated.
- Oncoplastic surgery can extend breast conservation in selected patients who would otherwise need removal of a larger amount of breast tissue.
- For invasive cancer undergoing breast conservation, 'no tumour on ink' is the standard negative-margin principle used in modern guidelines.
- For pure DCIS treated with breast conservation and whole-breast radiotherapy, a 2 mm negative margin is commonly considered adequate.
- Pure DCIS treated by breast-conserving surgery generally does not require sentinel lymph node biopsy.
- Sentinel lymph node biopsy is usually considered when mastectomy is performed for DCIS because a later sentinel procedure may no longer be reliable if invasion is found on final pathology.
- Sentinel lymph node biopsy remains appropriate for many clinically node-negative invasive cancers, but selected very low-risk patients can sometimes avoid axillary surgery.
- A positive sentinel lymph node does not automatically require full axillary lymph node dissection; the amount of nodal disease and the planned breast/radiation treatment matter.
- Avoiding unnecessary axillary dissection reduces the risk of arm lymphedema, numbness, shoulder restriction and chronic pain.
- Neoadjuvant systemic treatment can shrink the breast tumour or nodal disease and may make breast conservation or less extensive axillary surgery possible.
- HER2-positive and triple-negative cancers often require special consideration of neoadjuvant systemic treatment because treatment response can guide later therapy.
- Radiotherapy is usually part of breast-conserving treatment and may also be recommended after mastectomy in selected higher-risk situations.
- Reconstruction can be immediate or delayed and should be planned with the expected need for radiotherapy in mind.
- A patient may reasonably choose no reconstruction and request an aesthetic flat closure after mastectomy.
- Removing the opposite healthy breast is not routinely required for an average-risk patient with one-sided breast cancer.
- Genetic counselling and testing can influence surgical choices in patients with young age at diagnosis, strong family history, bilateral disease or other hereditary-risk features.
- The final pathology after surgery can change the stage and therefore the need for chemotherapy, endocrine therapy, HER2-directed therapy or radiotherapy.
- The goal of surgery is adequate cancer control with the least treatment burden that is safely appropriate for that individual patient.
Overview
Breast cancer surgery is planned as part of a wider multidisciplinary treatment pathway rather than as an isolated operation. The first step is to confirm the diagnosis with image-guided core biopsy and define the tumour biology, including hormone-receptor and HER2 status when invasive cancer is present. Breast imaging is then reviewed to determine the size and distribution of disease, while the axilla is assessed clinically and with imaging when appropriate. Additional systemic staging is used selectively according to stage, symptoms and tumour biology rather than routinely for every small early breast cancer.
For many patients with ductal carcinoma in situ (DCIS) or early invasive breast cancer, breast-conserving surgery is an oncologically sound alternative to mastectomy. Breast-conserving surgery removes the cancer with an adequate margin while preserving the remainder of the breast and is usually followed by radiotherapy. In suitable early breast cancer, breast-conserving surgery followed by appropriate radiotherapy provides survival outcomes equivalent to mastectomy. Mastectomy may be preferred or required when the extent of disease is large relative to the breast, disease is diffuse or multicentric and not suitable for conservation, margins remain involved despite reasonable re-excision, radiotherapy cannot be given, or the patient chooses mastectomy after informed discussion.
Modern breast surgery also includes oncoplastic techniques, which combine cancer removal with breast reshaping and can extend breast conservation in selected patients. For invasive cancer treated with breast conservation, the generally accepted surgical margin standard is no tumour on ink. For pure DCIS treated with breast-conserving surgery and whole-breast radiotherapy, a 2 mm negative margin is commonly used as the standard target, while final decisions still depend on the overall pathology and multidisciplinary plan.
Management of the lymph nodes under the arm has become increasingly selective. Sentinel lymph node biopsy remains an important staging procedure for many patients with clinically node-negative invasive breast cancer, but not every patient needs axillary surgery. Pure DCIS treated with routine breast-conserving surgery generally does not require sentinel-node staging, while sentinel-node biopsy is usually considered when mastectomy is performed for DCIS because later mapping may no longer be reliable if invasive cancer is found. In selected low-risk invasive cancers, omission of sentinel-node surgery may be reasonable after specialist assessment. Similarly, finding one or two positive sentinel nodes does not automatically mean a full axillary dissection is required; the breast operation, planned radiotherapy, tumour biology and nodal burden all influence the decision.
Some cancers should receive systemic treatment before surgery. Neoadjuvant chemotherapy and/or HER2-directed treatment is particularly useful when the tumour is large, the axillary nodes are involved, breast conservation may become possible after downstaging, or tumour biology such as HER2-positive or triple-negative disease makes response to preoperative treatment clinically important. After neoadjuvant therapy, the breast and axillary operation is planned according to the original stage, treatment response and residual disease.
Breast reconstruction may be immediate or delayed after mastectomy and can use an implant, the patient's own tissue, or a combination depending on anatomy, radiotherapy plans, comorbidity and patient preference. Not every patient wants reconstruction, and a well-planned flat closure is also a valid option. Risk-reducing surgery for the opposite breast is not routinely required for an average-risk patient with unilateral cancer; it is considered mainly when there is a strong hereditary or individual risk reason after genetic and specialist counselling.
The final surgical pathology determines tumour size, type and grade, margin status, lymph-node involvement and other features that influence the next stage of treatment. Radiotherapy, endocrine therapy, chemotherapy, HER2-directed therapy and other systemic treatments are then selected according to stage and tumour biology. The aim of modern breast-cancer surgery is therefore not simply to remove the breast or the lump, but to achieve oncologically sound local control while avoiding unnecessary surgery and preserving function and quality of life whenever safely possible.
Signs & symptoms
- A new breast lump or thickening that persists.
- A breast lump that is increasing in size or has suspicious imaging features.
- Skin dimpling, tethering or a change in breast contour.
- New nipple inversion or distortion.
- Spontaneous bloody or clear discharge from one nipple.
- Persistent unilateral nipple or areolar change such as ulceration or eczema-like change.
- A hard or enlarging lymph node in the armpit or above the collarbone.
- Breast swelling, redness or peau d'orange that does not behave like a simple infection.
- Some breast cancers cause no symptoms and are detected on screening or imaging.
How assessment and treatment are planned
- 1
Confirm the diagnosis with appropriate breast imaging and image-guided core biopsy whenever feasible before definitive cancer surgery.
- 2
Review histology and tumour biomarkers, including hormone-receptor and HER2 status for invasive cancer.
- 3
Assess both breasts and the regional lymph nodes clinically and with appropriate imaging.
- 4
Use additional systemic staging selectively when tumour stage, symptoms or biology make distant spread a realistic concern.
- 5
Discuss the case in an appropriate multidisciplinary setting when neoadjuvant treatment, complex breast conservation, reconstruction, radiotherapy planning or unusual pathology is relevant.
- 6
Decide whether breast-conserving surgery, mastectomy or another pathway best fits the tumour extent, breast size, genetic risk, radiotherapy feasibility and patient preference.
- 7
Plan sentinel lymph node biopsy or another axillary strategy only when it adds useful staging or treatment information.
- 8
If breast conservation is chosen, remove the tumour with an appropriate margin while preserving breast shape as far as oncologically safe.
- 9
Use oncoplastic techniques in selected cases when a larger resection is required but breast conservation remains feasible.
- 10
If mastectomy is required or preferred, plan skin-sparing, nipple-sparing, simple or other mastectomy approaches according to tumour location, anatomy and reconstruction strategy.
- 11
Discuss immediate reconstruction, delayed reconstruction or flat closure before mastectomy whenever applicable.
- 12
After neoadjuvant treatment, reassess the breast and axilla and tailor surgery to the original disease burden, response and residual disease.
- 13
Send the specimen for complete pathological assessment of tumour characteristics, margins and lymph nodes.
- 14
Review final pathology and coordinate radiotherapy and systemic treatment according to the definitive stage and tumour biology.
- 15
Arrange surveillance, rehabilitation and survivorship follow-up after completion of treatment.
Preparation
- Bring mammography, ultrasound and breast MRI reports and images when available.
- Bring the core-biopsy pathology report and biomarker results.
- Bring previous breast-operation or biopsy reports.
- Tell the surgeon about a strong family history of breast, ovarian, pancreatic or prostate cancer.
- Discuss whether genetic counselling or testing should be completed before choosing the definitive breast operation.
- Tell the team about previous chest or breast radiotherapy.
- Bring a full medication list, particularly anticoagulants, antiplatelet medicines and diabetes medicines.
- Do not stop blood-thinning medicines without an agreed perioperative plan.
- Discuss smoking, diabetes, obesity and other factors that may affect wound healing or reconstruction.
- If mastectomy is being considered, ask about reconstruction options, timing and the alternative of aesthetic flat closure.
- If breast conservation is planned, ask whether postoperative radiotherapy is expected and whether oncoplastic reshaping may be useful.
- If axillary surgery is planned, discuss whether the intention is sentinel-node biopsy or full axillary dissection and why.
- If chemotherapy or targeted treatment may be needed before surgery, complete multidisciplinary oncology review before scheduling the definitive operation.
Recovery and aftercare
- Attend the postoperative visit to review the final pathology, margins and lymph-node findings.
- Follow wound and drain-care instructions after mastectomy, reconstruction or axillary surgery.
- Begin shoulder and arm exercises as advised to reduce stiffness while protecting the wound.
- Report increasing redness, fever, wound discharge, rapidly increasing swelling or severe pain.
- Report significant arm swelling, heaviness or tightness after lymph-node surgery because early lymphedema assessment can be helpful.
- Attend the medical-oncology and radiation-oncology appointments recommended after final pathology.
- After breast-conserving surgery, complete planned radiotherapy unless the multidisciplinary team has specifically advised that omission is appropriate.
- Take endocrine therapy, HER2-directed therapy or other systemic treatment exactly as prescribed when indicated.
- After reconstruction, follow the plastic-surgery or reconstructive team's activity and wound-care instructions.
- Continue surveillance according to the breast-cancer follow-up plan, including imaging of remaining breast tissue when appropriate.
- Seek support for persistent pain, body-image concerns, anxiety, menopausal symptoms or sexual-health concerns rather than treating survivorship as a purely surgical issue.
Risks and possible complications
- Bleeding or haematoma.
- Wound infection.
- Seroma, especially after mastectomy or axillary surgery.
- Delayed wound healing or skin-edge necrosis.
- Need for further breast surgery if margins remain involved after breast-conserving surgery.
- Change in breast shape, asymmetry or contour after breast-conserving surgery.
- Numbness or altered sensation of the breast, chest wall or upper inner arm.
- Shoulder stiffness after axillary or extensive breast surgery.
- Arm lymphedema, with risk increasing as axillary surgery and radiotherapy become more extensive.
- Chronic pain or nerve-related discomfort.
- Flap, implant or wound complications when reconstruction is performed.
- Need for revision surgery after reconstruction or oncoplastic surgery.
- Local or regional cancer recurrence despite appropriate treatment.
- Distant recurrence depending on the biology and stage of the original cancer.
- Psychological distress, body-image change and sexual-health concerns after cancer treatment.
When to seek medical care
- SOON: A new breast lump that persists beyond the next menstrual cycle or is present after menopause.
- SOON: A breast lump that is enlarging, hard, fixed or associated with skin or nipple change.
- SOON: Spontaneous bloody or clear discharge from one nipple.
- SOON: New nipple inversion, skin tethering or persistent unilateral nipple/areolar ulceration.
- SOON: An enlarging or hard axillary or supraclavicular lymph node.
- SOON: Any biopsy result showing breast cancer, DCIS or a high-risk lesion needing specialist planning.
- SOON: New symptoms or a new breast/axillary abnormality after previous breast-cancer treatment.
- URGENT: Rapid breast swelling, diffuse redness or peau d'orange when inflammatory breast cancer is a concern.
- URGENT: A breast wound or tumour that is bleeding significantly, infected or causing uncontrolled pain.
- URGENT: Severe breathlessness, new neurological symptoms or another acute problem in a patient with known advanced breast cancer.
Myth vs fact
Frequently asked questions
Sources
- National Cancer Institute. Breast Cancer Surgery.
- National Cancer Institute. Breast Cancer Treatment (PDQ) — Health Professional Version.
- American Society of Breast Surgeons. Resource Guide on Breast Conserving Surgery. 2026.
- American Society of Breast Surgeons. Resource Guide on Axillary Management for Patients With In-Situ and Invasive Breast Cancer. 2026.
- ESMO Pocket Guidelines. Early Breast Cancer: diagnosis, treatment and follow-up.
Medically reviewed by Dr. Shams Alam Mohammed Tahir, MBBS, MS (General Surgery). Last reviewed 2026-10-09.